A replication-deficient rSV40 mediates liver-directed gene transfer and a long-term amelioration of jaundice in gunn rats

Gastroenterology

Volumn 119, Issue 5, 2000, Pages 1348-1357

  Sauter, Bernhard V ^a,b   Parashar, Bhupesh ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE PIGMENT; BILIRUBIN; BILIRUBIN GLUCURONOSIDE GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE;

ANIMAL; ARTICLE; BILE; BLOOD; CELL STRAIN COS1; CHEMISTRY; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETICS; GUNN RAT; HUMAN; JAUNDICE; LIVER; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; RETREATMENT; SIMIAN VIRUS 40; TRANSGENE; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; BILE; BILE PIGMENTS; BILIRUBIN; COS CELLS; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GLUCURONOSYLTRANSFERASE; HUMANS; JAUNDICE; LIVER; MALE; RATS; RATS, GUNN; RETREATMENT; SIMIAN VIRUS 40; TRANSGENES; VIRAL LOAD; VIRUS REPLICATION;

EID: 0034320049     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.19577     Document Type: Article

References (39)

1. Lu M, Zhang N, Maruyama M, Hawley RG, Ho AD. Retrovirusmediated gène expression in hematopoietic cells correlates inversely with growth factor stimulation. Hum Gene Ther 1996;7: 2263-2271.
2. Corbeau P, Kraus G, Wong-Staal F. Transduction of human macrophages using a stable HIV-l/HIV-2-derived gene delivery system. Gene Ther 1998;5:99-104.
3. Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998;4:354-357.
4. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther 1998;80:35-47.
5. Deppert W, Schirmbeck R. The nuclear matrix and virus function. Int Rev Cytol 1995;162A:485-537.
6. Mortimer EA Jr, Lepow ML, Gold E, Robbins FC, Burton GJ, Fraumeni JF Jr. Long-term follow-up of persons inadvertently inoculated with SV40 as neonates. N Engl J Med 1981;305:15171518.
7. Shah K, Nathanson N. Human exposure to SV40: review and comment. Am J Epidemiol 1976;103:1-12.
8. Strickler HD, Rosenberg PS, Devesa SS, Hertel J, Fraumeni JF Jr, Goedert JJ. Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates [see comments]. JAMA 1998:279:292-295.
9. Bennett ER, Naujokas M, Hassell JA. Requirements for speciesspecific papovavirus DNA replication. J Virol 1989;63:5371-5385.
10. Breau WC, Atwood WJ, Norkin LC. Class I major histocompatibility proteins are an essential component of the simian virus 40 receptor. J Virol 1992;66:2037-2045.
11. Stang E, Kartenbeck J, Parton RG. Major histocompatibility complex class I molecules mediate association of SV40 with caveolae. Mol Biol Cell 1997;8:47-57.
12. Hummeler K, Tomassini N, Sokol F. Morphological aspects of the uptake of simian virus 40 by permissive cells. J Virol 1970;6: 87-93.
13. Mackay RL, Consigli RA. Early events in polyoma virus infection: attachment, penetration, and nuclear entry. J Virol 1976;19: 620-636.
14. Frost E, Bourgaux P. Decapsidation of polyoma virus: identification of subviral species. Virology 1975:68:245-255.
15. Mohr IJ, Fairman MP, Stillman B, Gluzman Y. Large T-antigen mutants define multiple steps in the initiation of simian virus 40 DNA replication. J Virol 1989;63:4181-4188.
16. Bute! JS, Jarvis DL. The plasma-membrane-associated form of SV40 large tumor antigen: biochemical and biological properties. Biochim Biophys Acta L986;865:171-195.
17. Schirmbeck R, Bohm W, Reimann J. DNA vaccination primes MHC class l-restricted, simian virus 40 large tumor antigenspecific CTL in H-2d mice that reject syngeneic tumors. J Immunol 1996;157:3550-3558.
18. Fanning E. Introduction to simian virus 40: getting by with more than a little help from r.s host cell. Dev Biol Stand 1998;94:3-8.
19. Strayer DS. SV40 as an effective gene transfer vector in vivo. J Biol Chem 1996;271:24741-24746.
20. Strayer DS, Milano J. SV40 mediates stable gene transfer in vivo. Gene Ther 1996;3:581-587.
21. Strayer DS, Kondo R, Milano J, Duan LX. Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cells. Gene Ther 1997:4:219-225.
22. Zern M, Ozaki I, Duar L-X, Pomerantz R, Liu S-L, Strayer DS. A novel SV40-based vec'.or successfully transduces and expresses an alpha 1-antitrypsin ribozyme in a human hepatoma-derived cell line. Gene Ther 1999:6:114-120.
23. Kondo R, Feitelson MA, Strayer DS. Use of SV40 to immunize against hepatitis B surface antigen: implications for the use of SV40 for gene transduction and its use as an immunizing agent. Gene Ther 1998;5:575-582.
24. Ritter JK. Yeatman M T, Ferreira P, Owens IS. Identification of a genetic alteration in the code for bilirubin UDP- glucuronosyltransferase in the UGT1 gene complex of a Crigler-Najjar type I patient. J Clin Invest 1992:90:150-155.
25. Wolkoff AW, Chowdhury JR, Gärtner LA, Rose AL, Biempica L, Giblin DR, Fink D, Arias IM. Clinical conference. Crigler-Najjar syndrome (type I) in ijn adult male. Gastroenterology 1979;76: 840-848.
26. Kaufman SS, Wood HP, Shaw BW Jr, Markin RS, Rosenthal P, Gridelli B, Vanderhool JA. Orthotopic liver transplantation for type I Crigler-Najjar syndrome. Hepatology 1986:6:1259-1262.
27. Seppen J, Bosma PJ, Goldhoorn BG, Bakker CT, Chowdhury JR, Chowdhury NR, Jansen PL, Oude Elferink RP. Discrimination between Crigler-Najjar tvpe I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest 1994; 94:2385-2391.
28. Strayer DS, Duan LX, Ozaki I, Milano J, Bobraski LE, Bagasra 0. Titering replication-defective virus for use in gene transfer. Biotechniques 1997;22 447-450.
29. Bosma PJ, Chowdhury NR, Goldhoorn BG, Hofker MH, Oude Elferink RP, Jansen PL, Chowdhury JR. Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-\lajjar syndrome, type I. Hepatology 1992; 15:941-947.
30. Peters WH, Allebes WA, Jansen PL, Poels LG, Capel PJ. Characterization and tissue specificity of a monoclonal antibody against human uridine 5'-diphosphate-glucuronosyltransferase. Gastroenterology 1987 ;93:162-169.
31. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sei U S A 1979; 76:4350-4354.
32. Trotman BW, Roy-Chowdhury J, Wirt GD, Bernstein SE. Azodipyrroles of unconjugated and conjugated bilirubin using diazotized ethyl anthranilate in dimethyl sulfoxide. Anal Biochem 1982:121: 175-180.
33. llan Y, Sauter B, Chowdhury NR, Reddy BV, Thummala NR, Droguett G, Davidson A, Ott M, Horwitz MS, Chowdhury JR. Oral tolerization to adenoviral proteins permits repeated adenovirusmediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology 1998;27:1368-1376.
34. Chowdhury JR, Chowdhury NR, Wu G, Shouval R, Arias IM. Bilirubin mono- and diglucuronide formation by human liver in vitro: assay by high-pressure liquid chromatography. Hepatology 1981; 1:622-627.
35. Fox IJ, Chowdhury JR, Kaufman SS, Goertzen TC, Chowdhury NR, Warkentin PI, Dorko K, Sauter BV, Strom SC. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation [see comments]. N Engl J Med 1998;338:1422-1426.
36. Fevery J, Blanckaert N, Heirwegh KP, Préaux AM, Berthelot P. Unconjugated bilirubin and an increased proportion of bilirubin monoconjugates in the bile of patients with Gilbert's syndrome and Crigler-Najjar disease. J Clin Invest 1977;60:970-979.
37. Nowicki MJ, Poley JR. The hereditary hyperbilirubinaemias. Baillieres Clin Gastroenterol 1998;12:355-367.
38. Strayer DS, Zern MA. Gene delivery to the liver using simian virus 40-derived vectors. Semin Liver Dis 1999;19:71-81.
39. Strayer DS. Therapeutic gene delivery using SV40-based vectors: why and how? Drug News Persp (in press).